NCT00381212View on ClinicalTrials.gov

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

November 30, 2008

Conditions
HIV SeropositivityAcquired Immunodeficiency Syndrome
Interventions
BIOLOGICAL

AGS-004

Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.

Trial Locations (1)

H2X 2P4

Immunodeficiency Service/Montreal Chest Institute, Montreal

Sponsors

Collaborators (1)

Argos Therapeutics
All Listed Sponsors
collaborator

Université de Montréal

OTHER

collaborator

Argos Therapeutics

INDUSTRY

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT00381212 - A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. | Biotech Hunter | Biotech Hunter